Understanding Psilocybin and Neuroplasticity

Overview: Psychedelics like LSD, psilocybin, and DMT can enhance neuroplasticity. Neuroplasticity is the brain’s ability to reorganize itself by forming new neural connections and altering existing ones. There are two main types of neuroplasticity: structural and functional. Psilocybin has been shown to induce structural neuroplasticity, involving the growth of new neurons, synapses, and dendrites, increasing the complexity of neural networks, as well as functional neuroplasticity, improving the efficiency and strength of existing neural connections, enhancing communication between neurons. Additionally, psilocybin can reopen critical learning periods, particularly for social reward learning, making the brain more receptive to social experiences. These effects contribute to psilocybin’s potential as a therapeutic tool for conditions like depression, anxiety, and addiction. However, more research is necessary to fully understand and safely implement these treatments.

‍

Psychedelics and Neuroplasticity: The Science Explained

Psychedelics, including classic compounds such as lysergic acid diethylamide (LSD), psilocybin (the psychoactive compound found in magic mushrooms), and N,N-Dimethyltryptamine (DMT), share a common mechanism of action: partial agonism at the serotonin 5-HT2A G protein-coupled receptors. But what does this mean?

‍

Simply put, these substances bind to and activate the 5-HT2A receptors in the brain, though not fully, which is what “partial agonism” refers to. These receptors are involved in a range of important functions such as learning and memory, pain perception, the sleep-wake cycle, perception, and attention.

‍

When psychedelics activate the 5-HT2A receptors, certain neurons in the cortex increase the frequency of their firing rate, meaning they send electrical signals more rapidly. This increased activity is significant because these neurons are found in various regions of the brain, which may explain why psychedelics can influence a wide array of cognitive, perceptual, and emotional functions.

‍

Beyond their effects on the 5-HT2A receptor, psychedelics also trigger a cascade of other processes that enhance neuroplasticity—the brain’s ability to reorganize itself by forming new neural connections. Two notable models that help explain this are the psychoplastogen model and the critical period for social reward learning model.

‍

Through these mechanisms, psychedelics may promote the growth of new neural pathways and the strengthening of existing ones, potentially leading to lasting changes in brain function and behavior.

‍

Psilocybin and Neuroplasticity: Understanding Structural and Functional Changes 

Animal studies exploring the effects of psilocybin have revealed its remarkable ability to induce both structural and functional changes in neuroplasticity. Neuroplasticity refers to the brain's ability to reorganize itself by forming new neural connections and altering existing ones.

‍

Let’s break down the differences between these two types of neuroplasticity.

‍

• Structural Neuroplasticity involves the brain's capacity to physically change its structure by forming new neural connections. This can include the growth of new neurons, the development of new synapses (connections between neurons), and the increase in the complexity of neural networks.

• Functional Neuroplasticity, on the other hand, refers to changes in the efficiency and strength of existing neural connections. This type of neuroplasticity enhances how effectively the brain's existing neural networks communicate and process information.

‍

One key aspect of neuroplasticity that psilocybin influences is “synaptic plasticity,” which is the brain’s ability to adapt by creating new connections between its nerve cells.

‍

Animal studies have shown that psilocybin can activate certain genes in ways that promote synaptic plasticity. For example, psilocybin can trigger the expression of immediate early genes (IEGs) and brain-derived neurotrophic factor (BDNF). IEGs act as signals that tell the brain to prepare for change, while BDNF functions as a growth factor that encourages brain cells to form new connections and increase in size.

‍

Psilocybin has also been shown to stimulate the brain to build more connections between brain cells, a process known as synaptic growth or synaptogenesis.

‍

Additionally, psilocybin encourages neurons to grow more branches, known as dendrites, which improves their ability to connect and share information. This process is called dendritic growth.

‍

Research also suggests that psilocybin may strengthen the connections between neurons over time, a phenomenon called long-term potentiation. Long-term potentiation is crucial for learning and memory, as it enhances the efficiency of synaptic transmission.

‍

These structural and functional changes in neuroplasticity may underlie the therapeutic effects of psilocybin. By promoting both structural changes, such as synaptic and dendritic growth, and functional changes, such as improved synaptic efficiency, psilocybin-assisted therapy may help to rewire the brain in beneficial ways.

‍

These findings have led to a new understanding of the therapeutic effects of psychedelics, emphasizing their role in enhancing neuroplasticity. This model suggests that psychedelics can be considered “psychoplastogens,” meaning substances that promote rapid and significant changes in brain structure and function.

‍

By promoting these changes, psilocybin-assisted therapy may offer a novel approach to addressing mood disorders, potentially providing relief where traditional therapies have failed.

‍

However, While these results are promising, translating them to human clinical settings is complex. Extensive research is needed to fully understand these mechanisms and how they might be used in psychedelic treatments. 

‍

Also, it’s important to note that neuroplasticity is not always beneficial. For example, changes in neuroplasticity within the brain's reward system following repeated use of addictive drugs have been associated with habitual and compulsive drug use.

‍

‍

Psilocybin and Neuroplasticity: Reopening of Critical Learning Periods

Recent research has highlighted the effects of psilocybin on neuroplasticity. Specifically, psilocybin’s active metabolite, psilocin, has shown the ability to reopen critical learning periods. So, what does this mean?

‍

When psilocybin is ingested, the body metabolizes it into psilocin, the compound that interacts with the brain to produce psychedelic effects. A recent study led by Dr. Gül Dölen, an Associate Professor in the Department of Neuroscience at the Brain Science Institute, investigated how psilocin impacts the brain’s learning processes, particularly in relation to neuroplasticity.

‍

Dr. Dölen and her team discovered that psilocybin can reopen a “critical period” for social reward learning. A critical period is a window of time during which the brain is especially receptive to learning specific skills or behaviors, demonstrating high neuroplasticity. This period is crucial for developing social skills because it’s when the brain most efficiently learns and adapts to social experiences.

‍

In their study, researchers observed that psilocin could reopen this critical period in adult mice. Typically, this window closes after a certain developmental stage, reducing neuroplasticity and making it harder for adult brains to learn from social cues and interactions as efficiently as during childhood. However, psilocin appears to temporarily reverse this closure, enhancing the brain’s ability to recognize and learn from social interactions that lead to positive outcomes or rewards.

‍

Another significant finding from the study is the role of oxytocin, a hormone associated with social bonding, trust, and emotional regulation. The researchers found that the ability of psilocin to reinstate social reward learning in adult mice is linked to changes in oxytocin levels. This suggests that psilocybin’s effects on social learning and neuroplasticity are partly mediated by this hormone.

‍

Furthermore, the duration of the psychedelic effects in humans was found to correlate with the length of the reopened critical learning period in mice. This implies that the longer the psychedelic experience, the longer the brain remains in this enhanced state of neuroplasticity.

‍

Reopening critical learning periods related to social reward means that psilocybin may boost the brain’s capacity to learn and adapt in specific areas, such as understanding and processing social interactions and rewards. This process can lead to improved social learning and behavior, showcasing neuroplasticity in action.

‍

This mechanism may be a key factor behind the therapeutic effects of psilocybin. By temporarily reactivating these critical learning periods, psilocin may facilitate adaptive changes in behavior and thought patterns, demonstrating the power of neuroplasticity. This could be particularly beneficial in treating conditions like depression, anxiety, and addiction, where altering maladaptive behaviors and thought processes is crucial.

‍

Psilocybin and Neuroplasticity: Implications for Mental Health Treatment

Psychedelics like LSD, psilocybin, and DMT enhance neuroplasticity by interacting with serotonin 5-HT2A receptors, leading to various cognitive, perceptual, and emotional effects. Neuroplasticity involves both structural changes, such as the growth of new neurons and synapses, and functional changes, like the strengthening of existing neural connections.

‍

Psilocybin  promotes synaptic plasticity, synaptogenesis, and dendritic growth, which improve neural connectivity. Research shows that psilocybin can reopen critical learning periods for social reward learning, enhancing the brain's ability to adapt to new social experiences. This process is partly mediated by oxytocin, a hormone linked to social bonding.

‍

These changes in neuroplasticity are thought to underpin the therapeutic effects of psilocybin, potentially offering new treatments for mood disorders, anxiety, and addiction. However, further research is needed to fully understand and safely implement these therapies.

‍

In summary, psilocybin's ability to enhance neuroplasticity and reopen critical learning periods positions it as a promising tool in the future of mental health treatment.